IGFBP6 Rekombinanter Antikörper

IGFBP6 Rekombinant Antikörper für WB, ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, ELISA

Konjugation

Unkonjugiert

CloneNo.

241724H5

Kat-Nr. : 84364-5-RR

Synonyme

IGF-binding protein 6, IGF binding protein 6, IBP-6, IBP6, IBP 6

---

• 

  WB analysis of human testis using 84364-5-RR

  human testis tissue were subjected to SDS PAGE followed by western blot with 84364-5-RR (IGFBP6 antibody) at dilution of 1:4000 incubated at room temperature for 1.5 hours.

• 

  Affinity and Kinetic Characterization of 84364-5-RR

  Biolayer interferometry (BLl) kinetic assays of 84364-5-RR against Human IGFBP6 were performed. The affinity constant is 0.259 nM.

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: humanes Hodengewebe

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:1000-1:8000

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Produktinformation

84364-5-RR bindet in WB, ELISA IGFBP6 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• Wirt / Isotyp: Kaninchen / IgG
• Klonalität: Rekombinant
• Typ: Antikörper
• Immunogen: Rekombinantes Protein
• Vollständiger Name: insulin-like growth factor binding protein 6
• Berechnetes Molekulargewicht: 25 kDa
• Beobachtetes Molekulargewicht: 34 kDa
• GenBank-Zugangsnummer: BC011708
• Gene symbol: IGFBP6
• Gene ID (NCBI): 3489
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein A purfication
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Insulin-like growth factor (IGF) binding protein (IGFBP6), a 240 amino acid protein, contains an IGFBP N-terminal domain and a thyroglobulin type-1 domain. It modulates the activity of IGF and shows independent effects of IGF, such as growth inhibition and apoptosis. It can decrease the proliferation and survival of cancer cells such as lung cancer cells and naso-pharyngeal cancer cells. IGFBP-6 is distinctive for its 50-fold higher binding affinity for IGF-II over IGF-I and this specificity makes it an attractive potential therapeutic candidate for IGF-II-dependent pediatric malignancies such as rhabdomyosarcoma (RMS). In addition, it was found that IGFBP6 can promote the migration of RMS cells in an IGF-independent manner, and MAPK pathways were involved in this process. Further study reported that IGFBP6 is one of most highly expressed proteins in varicose vein tissues and is involved in the proliferation of vascular smooth muscle cells (VSMCs), which may provide insights into the underlying pathogenesis of varicose vein.